{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:42:29Z","timestamp":1793065349753,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10549-026-07919-3","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T09:53:33Z","timestamp":1771840413000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"216","author":[{"given":"L.","family":"Sisca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"Polito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Silletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"La Cesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Scafetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. M.","family":"Gullotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Guarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Barnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Speziale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Troiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Foderaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Iuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cavalieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Calagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pantano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"17","key":"7919_CR1","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.3390\/cancers13174287","volume":"13","author":"S \u0141ukasiewicz","year":"2021","unstructured":"\u0141ukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanis\u0142awek A (2021) Breast cancer\u2014epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014an updated review. Cancers 13(17):4287","journal-title":"Cancers"},{"issue":"12","key":"7919_CR2","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41571-022-00687-1","volume":"19","author":"E Agostinetto","year":"2022","unstructured":"Agostinetto E, Gligorov J, Piccart M (2022) Systemic therapy for early-stage breast cancer: learning from the past to build the future. Nat Rev Clin Oncol 19(12):763\u2013774","journal-title":"Nat Rev Clin Oncol"},{"key":"7919_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1172108\/full","author":"L Zhu","year":"2023","unstructured":"Zhu L, Xu R, Yang L, Shi W, Zhang Y, Liu J et al (2023) Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review. Front Genet. https:\/\/doi.org\/10.3389\/fgene.2023.1172108\/full","journal-title":"Front Genet"},{"issue":"1","key":"7919_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10555-022-10075-x","volume":"42","author":"I Heidrich","year":"2023","unstructured":"Heidrich I, Deitert B, Werner S, Pantel K (2023) Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors. Cancer Metastasis Rev 42(1):161\u2013182","journal-title":"Cancer Metastasis Rev"},{"issue":"10","key":"7919_CR5","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","volume":"5","author":"I Garcia-Murillas","year":"2019","unstructured":"Garcia-Murillas I, Chopra N, Comino-M\u00e9ndez I, Beaney M, Tovey H, Cutts RJ et al (2019) Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol 5(10):1473\u20131478","journal-title":"JAMA Oncol"},{"issue":"2","key":"7919_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","volume":"34","author":"NC Turner","year":"2023","unstructured":"Turner NC, Swift C, Jenkins B, Kilburn L, Coakley M, Beaney M et al (2023) Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Ann Oncol 34(2):200\u2013211","journal-title":"Ann Oncol"},{"key":"7919_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00456","volume":"8","author":"JA Shaw","year":"2024","unstructured":"Shaw JA, Page K, Wren E, de Bruin EC, Kalashnikova E, Hastings R et al (2024) Serial postoperative circulating tumor DNA assessment has strong prognostic value during long-term follow-up in patients with breast cancer. JCO Precis Oncol 8:e2300456","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"7919_CR8","doi-asserted-by":"publisher","first-page":"14704","DOI":"10.1038\/s41598-020-71236-y","volume":"10","author":"L Cavallone","year":"2020","unstructured":"Cavallone L, Aguilar-Mahecha A, Lafleur J, Brousse S, Aldamry M, Roseshter T et al (2020) Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer. Sci Rep 10(1):14704","journal-title":"Sci Rep"},{"issue":"1","key":"7919_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41523-023-00607-1","volume":"10","author":"E Zaikova","year":"2024","unstructured":"Zaikova E, Cheng BYC, Cerda V, Kong E, Lai D, Lum A et al (2024) Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment. NPJ Breast Cancer 10(1):3","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"7919_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13058-025-02026-5","volume":"27","author":"M Dong","year":"2025","unstructured":"Dong M, Chen J, Lu N, Wang S, Wei W, Wang Z et al (2025) Unraveling breast cancer response to neoadjuvant chemotherapy through integrated genomic, transcriptomic, and circulating tumor DNA analysis. Breast Cancer Res BCR 27(1):64","journal-title":"Breast Cancer Res BCR"},{"issue":"1","key":"7919_CR11","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1186\/s12885-024-12689-6","volume":"24","author":"JH Chen","year":"2024","unstructured":"Chen JH, Addanki S, Roy D, Bassett R, Kalashnikova E, Spickard E et al (2024) Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA. BMC Cancer 24(1):1016","journal-title":"BMC Cancer"},{"issue":"8","key":"7919_CR12","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.15252\/emmm.201404913","volume":"7","author":"E Olsson","year":"2015","unstructured":"Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MHE et al (2015) Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med 7(8):1034\u20131047","journal-title":"EMBO Mol Med"},{"key":"7919_CR13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/PO.19.00292","volume":"4","author":"S Li","year":"2020","unstructured":"Li S, Lai H, Liu J, Liu Y, Jin L, Li Y, Liu F, Gong Y, Guan Y, Yi X, Shi Q (2020) Circulating tumor DNA predicts the response and prognosis in patients with early breast cancer receiving neoadjuvant chemotherapy. JCO Precis Oncol 4:244\u2013257","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"7919_CR14","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","volume":"6","author":"M Radovich","year":"2020","unstructured":"Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C et al (2020) Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial. JAMA Oncol 6(9):1410\u20131415","journal-title":"JAMA Oncol"},{"issue":"2","key":"7919_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","volume":"32","author":"MJM Magbanua","year":"2021","unstructured":"Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM et al (2021) Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol Off J Eur Soc Med Oncol 32(2):229\u2013239","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"9","key":"7919_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103687","volume":"9","author":"R Cutts","year":"2024","unstructured":"Cutts R, Ulrich L, Beaney M, Robert M, Coakley M, Bunce C et al (2024) Association of post-operative ctDNA detection with outcomes of patients with early breast cancers. ESMO Open 9(9):103687","journal-title":"ESMO Open"},{"issue":"6","key":"7919_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.annonc.2025.01.021","volume":"36","author":"I Garcia-Murillas","year":"2025","unstructured":"Garcia-Murillas I, Abbott CW, Cutts RJ, Boyle SM, Pugh J, Keough KC et al (2025) Whole genome sequencing-powered ctDNA sequencing for breast cancer detection. Ann Oncol 36(6):673\u2013681","journal-title":"Ann Oncol"},{"key":"7919_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103738","volume":"76","author":"R Wang","year":"2024","unstructured":"Wang R, Wang B, Zhang H, Liao X, Shi B, Zhou Y et al (2024) Early evaluation of circulating tumor DNA as marker of therapeutic efficacy and prognosis in breast cancer patients during primary systemic therapy. Breast Edinb Scotl 76:103738","journal-title":"Breast Edinb Scotl"},{"issue":"6","key":"7919_CR19","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","volume":"41","author":"MJM Magbanua","year":"2023","unstructured":"Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E et al (2023) Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell 41(6):1091-1102.e4","journal-title":"Cancer Cell"},{"issue":"3","key":"7919_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10549-024-07508-2","volume":"209","author":"I Garcia-Murillas","year":"2025","unstructured":"Garcia-Murillas I, Cutts RJ, Walsh-Crestani G, Phillips E, Hrebien S, Dunne K et al (2025) Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer. Breast Cancer Res Treat 209(3):493\u2013502","journal-title":"Breast Cancer Res Treat"},{"key":"7919_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00148","volume":"6","author":"F Cailleux","year":"2022","unstructured":"Cailleux F, Agostinetto E, Lambertini M, Roth\u00e9 F, Wu HT, Balcioglu M et al (2022) Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse. JCO Precis Oncol 6:e2200148","journal-title":"JCO Precis Oncol"},{"key":"7919_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.736769","volume":"11","author":"PH Lin","year":"2021","unstructured":"Lin PH, Wang MY, Lo C, Tsai LW, Yen TC, Huang TY et al (2021) Circulating tumor DNA as a predictive marker of recurrence for patients with stage II\u2013III breast cancer treated with neoadjuvant therapy. Front Oncol 11:736769","journal-title":"Front Oncol"},{"issue":"5","key":"7919_CR23","doi-asserted-by":"publisher","first-page":"684","DOI":"10.21037\/gs-24-115","volume":"13","author":"X Zhang","year":"2024","unstructured":"Zhang X, Feng R, Xu Y, Yang L, Xie F, Yang H et al (2024) Baseline circulating tumor DNA predicts long-term survival outcomes for patients with early breast cancer. Gland Surg 13(5):684\u2013696","journal-title":"Gland Surg"},{"key":"7919_CR24","doi-asserted-by":"crossref","unstructured":"Llombart-Cussac A, P\u00e9rez-Garc\u00eda J, Ruiz-Borrego M, Stradella A, Bermejo B, Escriv\u00e1-de-Roman\u00ed S, et al (2025) Circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2-positive early breast cancer: translational analysis of the PHERGain neoadjuvant tailored treatment study. San Antonio Breast Cancer Symposium. Abstract GS1\u201306","DOI":"10.1158\/1557-3265.SABCS25-GS1-06"},{"key":"7919_CR25","doi-asserted-by":"crossref","unstructured":"Cunningham N, Cutts RJ, Swift C, Dunne K, Dewan M, Kilburn L, et al (2025) Tissue-free circulating tumour DNA detection in patients with early triple-negative breast cancer from the c-TRAK-TN trial. San Antonio Breast Cancer Symposium. Abstract RF3\u201305","DOI":"10.1158\/1557-3265.SABCS25-RF3-05"},{"key":"7919_CR26","doi-asserted-by":"crossref","unstructured":"Balic M, Tang G, Young G, Rastogi P, Acosta J, Schneeweiss A, et al (2025) Evaluation of a whole-exome sequencing tumor-informed circulating tumor DNA MRD assay in patients with early triple-negative breast cancer: a prospective sub-study of the NSABP-B59\/GBG-96-GeparDouze trial. San Antonio Breast Cancer Symposium. Abstract RF4\u201303","DOI":"10.1158\/1557-3265.SABCS25-RF4-03"},{"key":"7919_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS620","author":"K Pfister","year":"2025","unstructured":"Pfister K, Huesmann S, Friedl TW, Fink A, Mehmeti F, Mergel F, Sch\u00e4ffler H, Heublein S, Hartkopf AD, Mueller V, Wiesmueller LM (2025) The SURVIVE study: liquid biopsy guided surveillance after intermediate- to high-risk early breast cancer. J Clinic Oncol. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS620","journal-title":"J Clinic Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07919-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07919-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07919-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T21:02:04Z","timestamp":1773522124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07919-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7919"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07919-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Giuseppe Tonini has served on advisory boards for Molteni, Novartis, PharmaMar, and MSD. Francesco Pantano has served on advisory boards for Lilly, Gilead, AstraZeneca, Novartis, and Daiichi Sankyo. Alessio Cortellini has received honoraria or consulting fees from Bristol-Myers Squibb, AstraZeneca, MSD Oncology, Regeneron, Amgen, Daiichi Sankyo\/AstraZeneca, Roche, Access Infinity, Ardelis Health, Iqvia, Alpha Sight, Capvision, techspert.io, Atheneum, Alira Health, Tegus, and Johnson & Johnson\/Janssen. All other authors declare no conflicts of interest. The declaration of interest form for Bruno Vincenzi is pending and will be provided upon request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"16"}}